Pular para o conteúdo principal
Ranking Invest

WVE - Wave Life Sciences Ltd.

Segmento: HealthcareWave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.

Análise Ranking Invest

Valor de Mercado
$ 717.91 Mi
IVR
-0.01Índice proprietário de comparação relativa: -0,01.
IVR2
-0.69Leitura proprietária complementar: -69%.
MLL
-0.69Leitura proprietária complementar: -69%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 453.52 Mi

Dívida Líquida

-$ 368.01 Mi

L4T

-$ 202.47 Mi

MM4T

-780.20%

Indicadores Básicos

ROE

-44.64%

Índices de Previsibilidade

Receita Líquida

G0.97

Lucro

D0.53

Margem

E1.49

Índices de Tendência

Receita Líquida

D-0.10

Lucro

E-4.10

Margem

D0.45

Índices de Endividamento

DIV/PAT

-0.81

DIV/L4T

1.82

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.